Jade Biosciences reported a net loss of $55.8 million for Q2 2026, driven by increased R&D expenses to $50.1 million and G&A costs of $8.9 million. The company holds $461.2 million in cash and investments, providing runway into late 2028 following a recent $172.5 million public offering. Clinically, JADE101 showed positive Phase 1 interim data for IgA nephropathy with potential for every-12-week dosing, prompting the start of a Phase 2 trial and plans for a Phase 3 study in early 2027. Dosing began in the Phase 1 rheumatoid arthritis trial for JADE201, while JADE301 is scheduled to enter Phase 1 trials in late 2026. Mark Eisner joined the board of directors. Jade Biosciences is a clinical-stage biotechnology company developing therapies for autoimmune diseases.
